Appeal panels are drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.
Read the appeal panel members' biographies and registered interests (Word).
The following non-executive directors are members of the appeal panel. You can read their profiles on our Board page.
- Read the profile of Dr Mark Chakravarty
- Read the profile of Jackie Fielding
- Read the profile of Professor Gary Ford CBE
- Read the profile of Dame Elaine Inglesby-Burke DBE
- Read the profile of Alina Lourie
- Read the profile of Professor Bee Wee
- Read the profile of Dr Justin Whatling
Adrian is vice president of health technology assessment (HTA) and access policy at Johnson & Johnson. He has worked in the life sciences industry for over 25 years. His experience is mainly in the fields of health economics, outcomes research, and reimbursement policy, across the pharmaceutical, medical device, and diagnostic sectors.
Adrian is actively engaged in numerous multi-stakeholder forums, where key issues of HTA and access policy are debated and shaped. These include the HTAi Policy Forum and initiatives that have brought regulators and HTA agencies together with companies, improving transparency and appreciation of different stakeholder perspectives.
Adrian served on NICE's technology appraisal committee between 2003 and 2020. He was on the board of directors for the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) between 2013 and 2015.
Kawitha is director of market access at Janssen. , She is responsible for the market access strategy across Europe, Middle East and Africa in haematology.
Kawitha has over 15 years of experience in the pharmaceutical industry. In her previous role at Amgen Ltd, she led the UK and Ireland Access Directorate and was a board member in the affiliate leadership team. She led the health economics, local market access and field-based NHS Partnership teams and was responsible for unlocking patient access for Amgen's portfolio of medicines. She was also responsible for developing company strategic policy positions on health technology assessment (HTA) through her membership in the Association of the British Pharmaceutical Industry Value and Access Group and the Scottish Medicines Consortium (SMC) User Group Forum.
Kawitha served as an industry member in the SMC New Drugs Committee from January 2019 to December 2020. She reviewed and developed preliminary HTA advice for numerous appraisals in her capacity as a committee member.
Patrick is executive director of World Wide Health Economics and Outcomes Research (WWHEOR) Markets at Bristol-Myers Squibb. He leads the team responsible for supporting country health technology assessment (HTA) submissions and access, for all countries outside of the US. He also leads WWHEOR HTA policy initiatives and is a member of the European Federation of Pharmaceutical Industries and Associations HTA Task force.
Previously, Patrick led the BMS UK and Ireland Market Access function responsible for the HTA submissions to NICE, Scottish Medicines Consortium, All Wales Medicines Strategy Group and National Centre for Pharmacoeconomics. He also led the Bristol-Myers Squibb HTA policy strategy with the Association of the British Pharmaceutical Industry.
Patrick worked at GSK for 14 years in sales and marketing, health economics and outcomes research, and market access. Prior to GSK, Patrick worked as an oncology pharmacist for 8 years.
Paul is the European patient engagement lead at Merck Sharp & Dohme (MSD), where he is the interface between the company and patient organisations at the EU level. He qualified in medicine at the Royal London Hospital and held clinical posts in cardiology, mainly in East London, before moving into the pharmaceutical industry to run clinical trials.
Paul's involvement in health technology assessment has included crafting some of the very early MSD submissions to NICE, and subsequently serving 10 years on a technology appraisal committee. He lectures on health technology assessment at King's College London and the University of Hertfordshire.
Paul is senior lecturer/honorary consultant in clinical pharmacology at Barts Health NHS Trust. He is a fellow of the Royal College of Physicians, the British Hypertension Society and the Faculty of Pharmaceutical medicine.
Rachel is a director in Pfizer's UK Health Economics and Market Access department. She develops strategic approaches to market access, reimbursement and patient access and delivers projects to help shape the future health technology assessment policy environment. Rachel also leverages health economic information to deliver health technology assessments to NICE, across the breadth of Pfizer's portfolio, through a team of health economists.
Rachel started her career at Wellcome, in the atherosclerosis field, and has been at Pfizer for 25 years. She previously held a number of positions within Pfizer's UK commercial organisation (medical affairs and internal consulting arm) and its research and development organisation. She led a variety of pre-clinical projects across a number of therapeutic areas, which culminated in her becoming head of the primary pharmacology department.
Paul is global vice president of market access at Smith & Nephew. He has worked in health economics and health services research for over 25 years, with roles in industry and academia.
Paul started his career in health economics at GlaxoSmithKline before moving to roles of increasing responsibility with Johnson & Johnson. After 10 years of industry experience, Paul moved into the academic sector. He was director of the York Health Economics Consortium at the University of York and then professor of health economics at Brunel University.
During this time, Paul contributed to numerous NICE guidelines and was also a member of the technology appraisal committee. He joined Smith & Nephew in 2011 and now has global responsibility for health economics and market access functions.
David is the associate director for health economics and outcomes research (HEOR) at Bristol-Myers Squibb (BMS) UK & Ireland. David leads the BMS HEOR team and oversees all health economic activities. He's accountable for ensuring scientifically robust evidence submission dossiers are prepared for all UK and Irish health technology appraisal bodies.
David has been active in health technology appraisals for over 10 years. He previously held positions with other Association of the British Pharmaceutical Industry (ABPI) member companies: Lundbeck, Novartis, and AstraZeneca.
David currently represents BMS at ABPI for health technology assessment related work streams. He was previously a member of NICE's topic selection panel for mental health and a health economist industry representative on the New Medicines Group for the All Wales Medicines Strategy Group.
David is chief executive of the Psoriasis and Psoriatic Arthritis Alliance (PAPAA), a UK patient charity, and an experienced patient advocate. He has promoted the patient and public perspective since the 1990s, following his retirement from commercial business due to the onset of psoriatic arthritis. Since then, across numerous committees, David has been involved in many aspects of patient advocacy and involvement. His approach is based on his own experiences and those of people has met and supported during his varied working and voluntary activities.
David previously worked at the National Eczema Society and the international non-governmental organisation Teaching-aids at Low Cost (TALC). He has been a lay member of the NICE technology appraisal committee and a Commission on Human Medicine (CHM) Gastroenterology, Rheumatology, Immunology and Dermatology expert advisory group (GRIDEAG). He has also provided lay and patient input to the Medicines and Healthcare products Regulatory Agency (MHRA).
David was a public and patient research reviewer for the National Institute for Health Research (NIHR). This included reviewing research proposals in low and middle income countries from a community engagement and involvement perspective.
Professor Jonathan Cohen (chair)
Jonathan is Emeritus professor of infectious diseases at Brighton and Sussex Medical School (BSMS) and visiting professor at Imperial College School of Medicine. His main research interests have been in severe bacterial infections and the causes, diagnosis and management of sepsis. This is a field in which he has an international reputation.
Jonathan trained in medicine at Hammersmith Hospital and later became chairman of the Department of Infectious Diseases and Microbiology. He was then appointed as the foundation dean of BSMS in 2003.
Jonathan is currently president of the International Society for Infectious Diseases, a trustee of Arthritis Research UK, a member of the Scientific Advisory Board of the Lister Institute and a non-executive director at Kings NHS Foundation Trust. He served as vice chair of the Medical Schools Council and was a member of the panel for the 2008 and 2014 Research Assessment Exercises.
Rosemary was a practising solicitor before joining the Law Society to investigate complaints against solicitors from clients. She left to set up her own advisory practice, lecture, and undertake conciliation as a consultant to the Law Society. After volunteering as an independent custody visitor and spending 10 years as a member of a Research Ethics Committee, Rosemary has concentrated on voluntary roles with a range of medical organisations.
Rosemary has been a member of NICE's interventional procedures advisory committee since 2011. She sits on committees of the Royal Colleges of Physicians and Pathologists and is a panel member for independent reviews of individuals and hospital services with the Royal Colleges of Surgeons and Obstetricians and Gynaecologists. She undertakes a variety of lay roles with the National School of Healthcare Science and Health Education England West Midlands, and she is a lay assessor for the United Kingdom Accreditation Service. She is also involved with the scoring of clinical excellence awards to medical consultants within the NHS on behalf of the Department of Health and Social Care.
Rosemary was previously a member of the Examination and Assessment Committee of the Royal College of Obstetricians and Gynaecologists and the patient liaison group of the Royal College of Anaesthetists. She was instrumental in the appointment of lay examiners for the MRCOG Part 3 Examination of the Royal College of Obstetricians and Gynaecologists and is currently a lay examiner there. She has been a lay examiner in the UK and abroad for the Royal College of Surgeons of England.
Professor Alan Silman (chair)
Alan is an epidemiologist and rheumatologist. He is currently professor of musculoskeletal health at Oxford University, with specific interests in device epidemiology and in multimorbidity. He has published over 500 research papers and was listed amongst the world's top 400 biomedical science researchers in 2013.
Alan was previously the medical director of Arthritis Research UK (ARUK), where he was responsible for providing the strategic direction and leadership to the charity's research and education activities. Before that, he was the director of ARUK's Epidemiology Unit in Manchester for 18 years. Until the end of 2011, Alan was a consultant rheumatologist at the Manchester Royal Infirmary.
Alan was a Fellow of the Academy of Medical Sciences and he was awarded honorary doctorates from University of East Anglia in 2009 and Keele University in 2012. Alan has been a member of the Medicines and Healthcare products Regulatory Agency (MHRA) Pharmacovigilance Expert Advisory Group, vice chair and then chair of the Epidemiological Assessment Panels of UK Universities Research Assessment Exercise (2002 and 2008). He was also the chairman of the Ministry of Defence panel of research into the health of servicemen and women.
Paddy Storrie (chair)
Paddy has been involved as a lay member with NICE since 2004, firstly as a member of the Citizens Council and then as a lay member on the technology appraisals committee.
Paddy has experience as a member of the Medicines and Healthcare products Regulatory Agency (MHRA) Patient and Public Engagement Expert Advisory Group. He is on the steering committee of the High Intensity Specialist Led Acute Care research project. He has spoken twice at the Forum of Health Technology Appraisal International, a clearing house made up of representatives of regulators, payer bodies, and health technology businesses.
From 2010 to 2011, Paddy sat on the Academy of Medical Science Working Group on the Regulation and Governance of Medical Research. Outside of education and health, he has been involved in long-term projects with Stonewall and The Soldiers' Charity.
Catherine is chief executive for ICUsteps, the intensive care patient and support charity, and has been a volunteer with them since 2007.
She has been a lay member for South Warks Clinical Commissioning Group and a chair for NICE Guideline 204 - Babies, Children and Young People’s Experience of Healthcare (published in Aug 2021).
Catherine has a particular interest in clinical research, having been involved with funding panels as a patient and public representative since 2013 and a co-applicant since 2010.
Health service representatives
Professor Peter Groves (chair)
Peter is a consultant interventional cardiologist at the University Hospital of Wales, and has a specialist interest in the regulation, health technology assessment and implementation of innovative medical technologies into clinical practice.
Peter is honorary professor at Cardiff University and at the Queen Mary University London where he contributes expertise to the Cardiovascular Innovation Programme based at the William Harvey Research Institute.
Peter is chair of Health Technology Wales, an organisation sponsored by the Welsh Government to identify, appraise and promote the adoption of medical technologies in NHS Wales.
Peter has worked with NICE since 2006 and has been a member on the Interventional procedures advisory committee, and chair of the Medical technologies advisory committee. Peter has worked with the MHRA since 2015 as a member and chair of the Devices expert advisory committee.
Peter’s past roles also include Director of Cardiothoracic Services at the University Hospital of Wales (2002-2009), President of the Welsh Cardiovascular Society (2006-2010) and Council member of the British Cardiovascular Society (2006-2010).
Professor Kiran Patel
Kiran is the interim chief executive officer and chief medical officer for University Hospitals Coventry and Warwickshire. He is also a practising consultant cardiologist.
In the voluntary sector, Kiran is chair of trustees to the South Asian Health Foundation charity (which he founded in 1999). He was also a trustee for 3 terms at the UK Health Forum from 2003 to 2012. He is a mentor for the Social Mobility Foundation, which encourages and mentors students from deprived communities into the healthcare sector and further education.
He has worked with NICE, the Royal Colleges and the Department of Health in healthcare policy and strategy for over 2 decades. He has published papers and books and lectured extensively in the field of cardiology and more widely on social determinants and healthcare systems and strategy.
Christopher is a specialist registrar in general surgery in South London. He qualified from Imperial College London in 2006, having completed his basic surgical training in North West London. In 2009 he became a member of the Royal College of Surgeons of England.
Christopher completed a Wellcome Trust funded PhD in stem cell biology and tissue engineering at Imperial College in 2014. He was awarded a National Institute for Health Research (NIHR) funded Academic Clinical Fellowship and Honorary Clinical Research Fellowship at Imperial College London.
Christopher’s research focuses on the evaluation of novel surgical technology and practice. He has co-authored over 60 peer reviewed publications.
Dr Biba Stanton (chair)
Biba is a consultant neurologist at King's College Hospital and South London & Maudsley NHS Trusts, with a clinical interest in functional neurological disorder (FND), and behavioural symptoms in neurological disease. She runs a specialist clinic for FND at King’s College Hospital and is part of the Maudsley neuropsychiatry service. She also leads the inpatient tertiary neurology service at King’s.
Biba has a PhD in psychology from King’s College London, and a strong track record of publications in neuroimaging, neuropsychology, and behavioural neurology. She is a principal investigator in FND trials.
Biba is a Council Member at the Association of British Neurologists, where she also sits on the Education Committee and Equality, Diversity and Inclusion Committee. She contributes to the NHS England National Individual Funding Request Panel.